GlaxoSmithKline Egypt S.A.E. specializes in the development, manufacture and marketing of medicines. Their products are for the treatment of diabetes, asthma, cancer, hepatic viruses, infections, allergies and gastro-intestinal and cardiovascular diseases.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
24/09/26	EGP 255.66	-3.02%	62,220
23/09/26	EGP 263.61	-2.77%	46,484
22/09/26	EGP 271.12	+3.12%	200,298
21/09/26	EGP 262.91	-3.94%	160,731
20/09/26	EGP 273.69	-2.43%	70,592

End-of-day quote Egyptian Exchange

More quotes

End-of-day quote Egyptian Exchange 24/09/2026			5-day change	1st Jan Change
255.66 ^EGP	-3.02%		-8.86%	+301.67%

08-13	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-17	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE

Market Cap	21.35B 412M 362M 342M 311M 583M 39.53B 587M 4.09B 1.58B 20.19B 1.55B 1.52B 64.9B	P/E 2024	17.3x	P/E 2025	24.9x
Enterprise Value	20.95B 405M 355M 335M 306M 572M 38.79B 576M 4.01B 1.55B 19.82B 1.52B 1.49B 63.69B	EV / Sales 2024	1.02x	EV / Sales 2025	1.32x
Free-Float	2.91%	Yield 2024	2.78%	Yield 2025	1.18%

08-13	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-17	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE
03-12	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-12	GlaxoSmithKline FY dividend EGP 0.75 per share	RE
03-12	GlaxoSmithKline FY consol profit EGP 213.2 million	RE
12-29	GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026	CI
11-19	GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	GlaxoSmithKline Q3 consol loss EGP 34.8 million	RE
12/08/25	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12/08/25	GlaxoSmithKline posts Q2 consol profit EGP 5.9 mln	RE
14/05/25	GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
14/05/25	Glaxosmithkline Reports Q1 Net Profit EGP 43.5 Million	RE
09/03/25	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2024	CI

10/03/22	GlaxoSmithKline E : Glaxo Smith Kline (BIOC.CA) - Listing Committee Decision	PU
20/12/21	GSK hires former Tesco boss Sir Dave Lewis to head up £40bn spin-off	AQ

GlaxoSmithKline S.A.E Share Price

Stocks

BIOC

EGS38171C012

Pharmaceuticals

Valuation: GlaxoSmithKline S.A.E

Chart: GlaxoSmithKline S.A.E

Latest news: GlaxoSmithKline S.A.E

Press Releases: GlaxoSmithKline S.A.E

Quotes and Performance

Price Extremes

Managers and Directors: GlaxoSmithKline S.A.E

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-3.02%
1 week	-8.86%
Current month	-24.96%
1 month	-43.56%
3 months	+257.87%
6 months	+325.04%
Current year	+301.67%

1 week	247.03	288
1 month	247.03	453
Current year	55.1	609
1 year	55.1	609
3 years	24.7	609
5 years	16.66	609
10 years	0	609

Director	Title	Age	Since
Sherine El-Ansari BRD	Director/Board Member	-	-
Ashraf Mohammed Ibrahim Mansour CHM	Chairman	-	-
Munir Ghabour Hanna BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLAXOSMITHKLINE S.A.E	-3.02%	-8.86%	+306.78%	+698.94%	412M
ELI LILLY AND COMPANY	+0.13%	+2.65%	+65.61%	+114.28%	1,055B
JOHNSON & JOHNSON	+0.20%	+0.46%	+52.60%	+69.24%	654B
ABBVIE INC.	-0.29%	+0.14%	+20.96%	+70.93%	467B
ROCHE HOLDING AG	-0.85%	+0.98%	+41.29%	+44.38%	348B
NOVARTIS AG	+0.71%	+4.08%	+22.24%	+29.51%	275B
ASTRAZENECA PLC	+1.23%	+0.42%	+14.57%	+12.13%	258B
AMGEN INC.	+2.11%	+7.51%	+52.89%	+55.37%	224B
GILEAD SCIENCES, INC.	+0.83%	+0.55%	+35.99%	+101.70%	187B
NOVO NORDISK A/S	0.00%	-10.14%	-29.94%	-60.30%	171B
Average	+0.02%	+0.01%	+58.30%	+113.62%	363.88B
Weighted average by Cap.	+0.02%	+1.32%	+41.57%	+67.90%

	2024	2025
Net sales	2.99B 57.77M 50.7M 47.88M 43.63M 81.68M 5.54B 82.26M 573M 222M 2.83B 217M 212M 9.09B	3.73B 72.06M 63.23M 59.72M 54.42M 102M 6.91B 103M 715M 277M 3.53B 271M 265M 11.34B
Net income	174M 3.36M 2.95M 2.79M 2.54M 4.75M 322M 4.79M 33.33M 12.91M 165M 12.62M 12.35M 529M	213M 4.12M 3.61M 3.41M 3.11M 5.82M 395M 5.86M 40.85M 15.82M 202M 15.46M 15.13M 648M
Net Debt	44.01M 850K 746K 705K 642K 1.2M 81.48M 1.21M 8.43M 3.27M 41.63M 3.19M 3.12M 134M	-398M -7.69M -6.75M -6.37M -5.81M -10.87M -737M -10.95M -76.23M -29.53M -376M -28.86M -28.24M -1.21B